Jan 16 (Reuters) - The U.S. Food and Drug Administration on Thursday declined to approve Atara Biotherapeutics' (ATRA.O), opens new tab therapy to treat patients with a rare cancer that develops ...
The FDA Thursday issued a Complete Response Letter to immunotherapy-focused Atara Therapeutics for its T cell therapy for transplant complications, marketed in Europe as Ebvallo, sending the company’s ...
It may be, she added, that weekly therapy sessions are simply not scalable to a broad population, and the field should explore light-touch alternatives, like single-session interventions and ...
For therapy manufacturers, “that failure rate needs to come way down, closer to what they would expect when manufacturing a traditional drug,” Afshar said. Additionally, installing a Mytos ...
Preliminary safety analyses demonstrated that repetitive ICV dosing of the B7-H3 targeted CAR T therapy up to 10×10 7 cells was well tolerated as an outpatient regimen and without lymphodepleting ...
Anger management therapy can include a host of different therapies such as cognitive behavioral therapy or psychodynamic therapy. Your therapist or psychologist will tailor any chosen therapy to ...
High manufacturing costs limit access to cell and gene therapies and make it harder to bring new products to market, according to VIVEbiotech CEO, Jon Alberdi, who says cheaper production ...
its lead autologous CAR T-cell therapy targeting the immune checkpoint B7-H3, for diffuse intrinsic pontine glioma (DIPG), a type of incurable pediatric brain tumor. "We are very pleased to have a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback